Andrew Dudum Sells 36,460 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

by · The Markets Daily

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CEO Andrew Dudum sold 36,460 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now owns 27,918 shares in the company, valued at $756,298.62. This represents a 56.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Dudum also recently made the following trade(s):

  • On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
  • On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.
  • On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $1.86 during midday trading on Tuesday, reaching $29.71. The company had a trading volume of 11,542,028 shares, compared to its average volume of 10,582,276. Hims & Hers Health, Inc. has a one year low of $8.44 and a one year high of $35.02. The stock has a market capitalization of $6.49 billion, a P/E ratio of 67.51 and a beta of 1.31. The stock’s fifty day moving average price is $27.68 and its 200-day moving average price is $21.91.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period last year, the firm earned ($0.04) earnings per share. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares in the last quarter. Quest Partners LLC lifted its holdings in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the period. CWM LLC grew its position in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 2,442 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on HIMS shares. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley began coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $25.13.

Read Our Latest Research Report on HIMS

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Featured Articles